|
|
Core-binding factor acute myeloid leukemia in first relapse: a retrospective study from the French AML Intergroup
A. Hospital
,
T. Prebet
,
S. Bertoli
,
X. Thomas
,
E. Tavernier
et al.
Journal articles
hal-01688071v1
|
Share
Gmail
Facebook
Twitter
LinkedIn
More
|
|
|
Chromosomal abnormalities are major prognostic factors in elderly patients with multiple myeloma: the intergroupe francophone du myélome experience
Hervé Avet-Loiseau
,
Cyrille Hulin
,
Loic Campion
,
Philippe Rodon
,
Gerald Marit
et al.
Journal articles
hal-01064339v1
|
Share
Gmail
Facebook
Twitter
LinkedIn
More
|
|
|
Achievement of at least very good partial response is a simple and robust prognostic factor in patients with multiple myeloma treated with high-dose therapy: long-term analysis of the IFM 99-02 and 99-04 Trials.
Jean-Luc Harousseau
,
Herve Avet-Loiseau
,
Michel Attal
,
Catherine Charbonnel
,
Frederic Garban
et al.
Journal articles
hal-00821143v1
|
Share
Gmail
Facebook
Twitter
LinkedIn
More
|
|
|
Dasatinib in high-risk core binding factor acute myeloid leukemia in first complete remission: a French Acute Myeloid Leukemia Intergroup trial
Nicolas Boissel
,
Aline Renneville
,
Thibaut Leguay
,
Pascale Cornillet Lefebvre
,
Christian Recher
et al.
Journal articles
inserm-01820455v1
|
Share
Gmail
Facebook
Twitter
LinkedIn
More
|
|
|
Rituximab and dose-dense chemotherapy for adults with Burkitt's lymphoma: a randomised, controlled, open-label, phase 3 trial
Vincent Ribrag
,
Serge Koscielny
,
Jacques Bosq
,
Thibaut Leguay
,
Olivier Casasnovas
et al.
Journal articles
inserm-01419476v1
|
Share
Gmail
Facebook
Twitter
LinkedIn
More
|
|
|
Incidence of ATRX mutations in myelodysplastic syndromes, the value of microcytosis
Charles Herbaux
,
Nicolas Duployez
,
Catherine Badens
,
Nicolas Poret
,
Claude Gardin
et al.
Journal articles
inserm-02913994v1
|
Share
Gmail
Facebook
Twitter
LinkedIn
More
|
|
|
Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial
Paolo A Ascierto
,
Michele Del Vecchio
,
Caroline Robert
,
Andrzej Mackiewicz
,
Vanna Chiarion-Sileni
et al.
Journal articles
inserm-01807340v1
|
Share
Gmail
Facebook
Twitter
LinkedIn
More
|
|
|
Long-term follow up of the FL2000 study comparing CHVP-interferon to CHVP-interferon plus rituximab in follicular lymphoma.
Emmanuel Bachy
,
Roch Houot
,
Franck Morschhauser
,
Anne Sonet
,
Pauline Brice
et al.
Journal articles
hal-00933219v1
|
Share
Gmail
Facebook
Twitter
LinkedIn
More
|
|
|
Bortezomib-doxorubicin-cyclophosphamide-dexamethasone induction followed by stem cell transplantation for primary plasma cell leukemia: a prospective phase II study of the IFM
Bruno Royer
,
Minvielle Stéphane
,
Momar Diouf
,
Murielle Roussel
,
Lionel Karlin
et al.
Journal articles
inserm-01273359v1
|
Share
Gmail
Facebook
Twitter
LinkedIn
More
|
|
|
Pomalidomide plus low-dose dexamethasone is active and well tolerated in bortezomib and lenalidomide-refractory multiple myeloma: Intergroupe Francophone du Myélome 2009-02
Xavier Leleu
,
Michel Attal
,
Bertrand Arnulf
,
Philippe Moreau
,
Catherine Traulle
et al.
Journal articles
hal-01064417v1
|
Share
Gmail
Facebook
Twitter
LinkedIn
More
|
|
|
Lenalidomide maintenance after stem-cell transplantation for multiple myeloma.
Michel Attal
,
Valerie Lauwers-Cances
,
Gerald Marit
,
Denis Caillot
,
Philippe Moreau
et al.
Journal articles
hal-00852275v1
|
Share
Gmail
Facebook
Twitter
LinkedIn
More
|